Results 131 to 140 of about 74,631 (338)
Stroke Mimicking Thalamotomy in Primary Familial Brain Calcification
Movement Disorders Clinical Practice, EarlyView.
Jaakko Kungshamn+4 more
wiley +1 more source
Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a well‐established therapy in advanced Parkinson's disease (PD) improving motor and non‐motor signs including sleep. The mechanisms of sleep improvement are insufficiently understood.
Julia Steinhardt+6 more
wiley +1 more source
The current study presents the creation of a straightforward and sensitive sensor based on ZnO/Co3O4 nanocomposite modified screen-printed electrode (ZnO/Co3O4NC/SPE) for levodopa determination. At ZnO/Co3O4NC/SPE, an oxidative peak for levodopa solution
Tan Wang+10 more
doaj +1 more source
Alpha Methyldopahydrazine as an Adjunct to Levodopa Therapy in Parkinson’s Disease [PDF]
D. W. Paty+3 more
openalex +1 more source
Abstract Background Antiparkinson medications are effective in improving Parkinson's disease (PD) motor symptoms such as bradykinesia, tremor, and rigidity. The impact of antiparkinson medication on gait speed is less clear. Objectives The primary aim was to determine the effects of antiparkinson medication on gait speed in PD. The secondary aim was to
Anson B. Rosenfeldt+10 more
wiley +1 more source
The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours. [PDF]
Malcolm K. Jones, I D Ramsay, P Jenner
openalex +1 more source
Abstract Background The long‐term efficacy of high‐frequency subthalamic nucleus deep brain stimulation (STN‐DBS) on freezing of gait (FOG) remains unclear. We aimed to study the mechanism and optimal therapeutic approach to long‐term post‐surgery FOG.
Raquel Barbosa+13 more
wiley +1 more source
Levodopa versus levodopa sparing in early parkinson’s disease: can we meet halfway?
Monotherapy is the recommended initial treatment for early Parkinson’s disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations.
Mayela Rodríguez-Violante+7 more
doaj +1 more source
Abstract Background Both autonomic dysfunction and low levels of physical activity could contribute to reduced cardiorespiratory fitness in people with Parkinson's disease (PD). However, the interrelationship between these concepts is not well understood.
Kars I. Veldkamp+5 more
wiley +1 more source